{"filing":{"accession_number":"0001193125-26-271449","cik":"0000921299","ticker":"KYNB","company_name":"KYNTRA BIO, INC.","form":"8-K","filing_date":"2026-06-15","report_date":null,"primary_document":"kynb-20260612.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/921299/000119312526271449/kynb-20260612.htm"},"events":[{"id":11171,"run_id":9791,"accession_number":"0001193125-26-271449","anchor_item_number":"5.07","event_type":"shareholder_vote_results","event_domain":"governance","is_material":true,"confidence":0.98,"summary":"This is a classic Item 5.07 disclosure reporting the results of the 2026 annual meeting of stockholders held on June 12, 2026. The filing details three matters voted upon: (1) election of Class III director Michael Kauffman, M.D., Ph.D. (96.04% approval), (2) advisory approval of named executive officer compensation (98.0% approval), and (3) ratification of PricewaterhouseCoopers LLP as independent auditor (99.5% approval). All three are routine shareholder votes with strong approval margins, making this a material disclosure of governance outcomes.","company_name":"KYNTRA BIO, INC.","ticker":"KYNB","filing_date":"2026-06-15","form":"8-K","submitted_at":null,"items":[{"id":7696,"accession_number":"0001193125-26-271449","item_number":"5.07","item_title":"Submission of Matters to a Vote of Security Holders.","event_type":"shareholder_vote_results","event_domain":"governance","is_material":true,"confidence":0.98,"reasoning":"This is a classic Item 5.07 disclosure reporting the results of the 2026 annual meeting of stockholders held on June 12, 2026. The filing details three matters voted upon: (1) election of Class III director Michael Kauffman, M.D., Ph.D. (96.04% approval), (2) advisory approval of named executive officer compensation (98.0% approval), and (3) ratification of PricewaterhouseCoopers LLP as independent auditor (99.5% approval). All three are routine shareholder votes with strong approval margins, making this a material disclosure of governance outcomes.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-06-16T10:02:26.315821+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":7696,"accession_number":"0001193125-26-271449","item_number":"5.07","item_title":"Submission of Matters to a Vote of Security Holders.","event_type":"shareholder_vote_results","event_domain":"governance","is_material":true,"confidence":0.98,"reasoning":"This is a classic Item 5.07 disclosure reporting the results of the 2026 annual meeting of stockholders held on June 12, 2026. The filing details three matters voted upon: (1) election of Class III director Michael Kauffman, M.D., Ph.D. (96.04% approval), (2) advisory approval of named executive officer compensation (98.0% approval), and (3) ratification of PricewaterhouseCoopers LLP as independent auditor (99.5% approval). All three are routine shareholder votes with strong approval margins, making this a material disclosure of governance outcomes.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-06-16T10:02:26.315821+00:00","company_name":"KYNTRA BIO, INC.","ticker":"KYNB","filing_date":"2026-06-15"}]}